Trial reportNeurology2018
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
Open access · bronzeAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.The European journal of neuroscience · 2022Pooled it
- Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.BMJ neurology open · 2021Pooled it
- [Tauopathies : From molecule to therapy].Der Nervenarzt · 2018Pooled it
- Neurofilament light is a treatment-responsive biomarker in CLN2 disease.Annals of clinical and translational neurology · 2019Trial
- Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.Molecular psychiatry · 2026Article
- Study protocol: double-blind, randomized, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patients with corticobasal syndrome (CBS).Neurological research and practice · 2026Article
- Distinct plasma inflammatory signatures reflect disease severity and progression in progressive supranuclear palsy: a prospective cohort study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Article
- A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.Nature medicine · 2026Article
- Neurofilament light chain as a diagnostic and prognostic biomarker in atypical parkinsonisms: current evidence, new data, challenges, and future directions.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Dementia in Progressive Supranuclear Palsy: A Narrative Review.Neurology and therapy · 2026Review
- Assessment of Mitochondrial DNA Copy Number in Progressive Supranuclear Palsy Patients: Evidence From a Pilot Study.European journal of neurology · 2026Article
- Large-scale identification of protein biomarkers and therapeutic targets in heart and brain disease.Nature cardiovascular research · 2026Article
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- Plasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy.Journal of neurology · 2025Observational
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Blood-based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real-world implementation, clinical utility, and diagnostic performance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Tauopathy strains differentially replicate in vitro in the presence of mutant tau monomer.Neurobiology of disease · 2025Article
- Subcortical tau burden correlates with regional brain atrophy and plasma markers in four-repeat tauopathy parkinsonism.Journal of Parkinson's disease · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Julio C RojasFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD. jrojasmartinez@memory.ucsf.edu.
Jee BangFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD.
Iryna V LobachFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD.
Richard M TsaiFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD.
Gil D RabinoviciFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD.
Bruce L MillerFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD.
Adam L BoxerFrom the Memory and Aging Center, Department of Neurology (J.C.R., R.M.T., G.D.R., B.L.M., A.L.B.), and Department of Epidemiology and Biostatistics, Division of Biostatistics (I.V.L.), University of California, San Francisco; and Department of Neurology (J.B.), Johns Hopkins University School of Medicine, Baltimore, MD.
AL-108-231 Investigators
Johns Hopkins University · US
Funding
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MUC Irvine Alzheimer's Disease Research Center Induced Pluripotent Stem Cell CoreP50AG016573 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI LAFERLA, FRANK M · 2000 to 2019
$37.0MPrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUANG, YADONG · 2004 to 2018
$27.1MThe Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1MThe Frontotemporal Lobar Degeneration Neuroimaging InitiativeR01AG032306 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2009 to 2013
$10.0MTraining - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4MDecision-Making in Genetic FTDR01AG022983 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIONG, WINSTON · 2004 to 2021
$6.0MEffects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2MEye Movement Control in Normal Elderly and MCIR01AG031278 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2009 to 2013
$1.2MNIA NIH HHS P01 AG019724NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG022983NIA NIH HHS R01 AG031278NIA NIH HHS R01 AG032306NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG048234NINDS NIH HHS U54 NS092089
Abstract
objectiveTo determine the ability of CSF biomarkers to predict disease progression in progressive supranuclear palsy (PSP).
methodsWe compared the ability of baseline CSF β-amyloid
resultsHigher CSF NfL concentration predicted more rapid decline (biomarker × time interaction) over 52 weeks in PSPRS (
conclusionsBoth CSF p-tau and NfL correlate with disease severity and rate of disease progression in PSP. The inverse correlation of p-tau with disease severity suggests a potentially different mechanism of tau pathology in PSP as compared to Alzheimer disease.
Indexed as
AgedAmyloid beta-PeptidesBiomarkersBrainCentral Nervous System AgentsDisease ProgressionDouble-Blind MethodFemaleHumansLongitudinal StudiesMaleNeurofilament ProteinsOligopeptidesPeptide FragmentsPhosphorylationPrognosisAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersCentral Nervous System AgentsdavunetideMAPT protein, humanneurofilament protein LNeurofilament ProteinsOligopeptidesPeptide Fragmentstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.